EP Patent

EP3404100A1 — Multiple exon skipping compositions for dmd

Assigned to Sarepta Therapeutics Inc · Expires 2018-11-21 · 7y expired

What this patent protects

Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.

USPTO Abstract

Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.

Drugs covered by this patent

Patent Metadata

Patent number
EP3404100A1
Jurisdiction
EP
Classification
—
Expires
2018-11-21
Drug substance claim
No
Drug product claim
No
Assignee
Sarepta Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.